Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Artificial Intelligence (AI) Tele-Oncology Radiation Dose Scheduler Market Growth Potential: How Will Market Size Shift Through 2030?
The artificial intelligence (AI) tele-oncology radiation dose scheduler market has experienced significant expansion in recent years. It is projected to grow from $0.81 billion in 2025 to $0.99 billion in 2026, at a compound annual growth rate (CAGR) of 23.3%. The market’s growth in previous periods can be attributed to an increasing need for remote cancer treatment planning, the rising adoption of tele-oncology platforms, a growing demand for precise radiation dose calculation, the expanding use of AI in oncology decision support, a worldwide rise in cancer incidence, the advancing digital transformation within hospitals, the increasing deployment of cloud-based medical systems, an escalating need for workflow automation in radiotherapy, a growing focus on reducing treatment errors, and the increasing adoption of smart oncology scheduling tools.
The artificial intelligence (AI) tele-oncology radiation dose scheduler market is expected to demonstrate significant growth in the coming years, with its valuation predicted to reach $2.28 billion by 2030, growing at a compound annual growth rate (CAGR) of 23.0%. This anticipated expansion during the forecast period can be attributed to factors such as the broadening of tele-oncology networks, the increasing uptake of AI-enabled treatment planning platforms, a heightened requirement for automated dose calculation systems, the adoption of cloud-based oncology scheduling modules, the deployment of predictive oncology algorithms, the creation of remote radiotherapy review tools, the demand for precise cancer care, the incorporation of AI tools within oncology departments, strategic partnerships between AI vendors and cancer centers, and the rising acceptance of tele-radiation workflows. Prominent trends throughout this period include advancements in AI-driven radiotherapy dose prediction, further development in cloud-based oncology scheduling platforms, enhancements in real-time dose optimization engines, innovations in automated treatment planning systems, new developments in predictive oncology algorithms, new virtual radiation oncology workflows, the integration of tele-oncology with hospital information systems, the merging of AI dose schedulers with imaging platforms, the inclusion of remote dose-review tools for oncologists, and the formation of multi-center tele-radiation networks.
Get A Free Sample Report With In-Depth Market Insights:
Artificial Intelligence (AI) Tele-Oncology Radiation Dose Scheduler Market Industry Drivers: What’s Behind The Revenue Growth?
The escalating occurrence of cancer is anticipated to drive the expansion of the artificial intelligence (AI) tele-oncology radiation dose scheduler market moving forward. Cancer is defined as a disease characterized by the uninhibited proliferation and dissemination of atypical cells, which can harm nearby tissues and organs if not adequately managed. The incidence of cancer is on the rise, attributed to lifestyle-related factors like unhealthy eating habits, smoking, alcohol consumption, and contact with environmental contaminants, all of which elevate the likelihood of developing various cancers. Artificial intelligence (AI) tele-oncology radiation dose schedulers facilitate cancer treatment by optimizing and tailoring radiation therapy plans through remote, data-driven evaluations. They contribute to better patient outcomes by guaranteeing accurate dosing, reducing delays in treatment, and enabling uniform care across different geographical areas. As an illustration, in October 2025, NHS Digital, a UK government body, noted 354,820 new cancer diagnoses recorded in England in 2023, averaging 972 diagnoses each day. This represented an increase of 8,605 cases compared to 2022, with prostate cancer being the most frequently diagnosed at 58,137 new cases, indicating a 6% rise in registrations over the previous year. Hence, the growing prevalence of cancer is fueling the growth of the artificial intelligence (AI) tele-oncology radiation dose scheduler market.
Artificial Intelligence (AI) Tele-Oncology Radiation Dose Scheduler Market Segment Landscape: Which Areas Lead Development?
The artificial intelligence (AI) tele-oncology radiation dose scheduler market covered in this report is segmented –
1) By Component: Software, Hardware, Services
2) By Technology: Machine Learning Algorithms, Natural Language Processing, Computer Vision, Predictive Analytics
3) By Deployment Mode: On-Premise (Local Installation), Cloud-Based (SaaS), Hybrid Deployment
4) By Application: Auto-Contouring And Segmentation (OAR Or Target), Treatment Plan Generation And Optimization, Dose Prediction And Quality Assurance (QA), Workflow And Resource Scheduling Optimization, Adaptive Radiotherapy Planning
5) By End-User: Hospitals, Cancer Treatment Centers, Research Institutes, Other End-Users
Subsegments:
1) By Software: Analytics And Reporting Software, Recommendation Engine Software, Natural Language Processing Software, Machine Learning Model Management Tools, Computer Vision Software, Integration And API Management Software, Mobile And Web Application Software
2) By Hardware: AI-Optimized Servers, Edge Computing Devices, Sensors And IoT Devices, Smart Cameras, GPUs And AI Accelerators, Storage Systems, Networking And Connectivity Hardware
3) By Services: Consulting Services, Implementation And Integration Services, Training And Support Services, Managed AI Services, Maintenance And Upgradation Services, Custom AI Development Services, Data Management And Annotation Services
#Artificial Intelligence (AI) Tele-Oncology Radiation Dose Scheduler Market Growth Trends: What’s Shaping The Future Outlook?
Leading companies in the AI tele-oncology and radiation therapy market are prioritizing the development of sophisticated solutions, such as AI-powered dose prediction, to forecast personalized radiation dose distributions and thereby enhance the efficiency of treatment planning. These AI-powered dose prediction platforms serve as software solutions designed to analyze imaging and anatomical data, generate clinically attainable 3D dose distributions, and facilitate timely adjustments for optimizing therapy. For instance, in March 2025, MVision AI, a Finland-based health-tech company, introduced Dose+. This AI-powered dose prediction platform features specialized models for prostate and pelvic lymph node cases, customizes dose distributions for each patient’s unique anatomy, and supports integration with standard treatment planning systems via DICOM to streamline planning workflows. The introduction of Dose+ signifies a considerable technological stride, integrating AI-driven dose prediction into routine clinical practice, connecting traditional planning with automated, patient-specific optimization, and supplying clinicians with a scalable, efficient tool for precise, personalized radiation therapy.
Artificial Intelligence (AI) Tele-Oncology Radiation Dose Scheduler Market Company Landscape And Competitive Strategy
Major companies operating in the artificial intelligence (AI) tele-oncology radiation dose scheduler market are IBM Corporation, Siemens Healthineers AG, GE HealthCare Technologies Inc., Koninklijke Philips N.V., Varian Medical Systems Inc., Elekta AB, Shanghai United Imaging Healthcare Co. Ltd., Accuray Incorporated, Brainlab AG, RaySearch Laboratories AB, MIM Software Inc., Sun Nuclear Corp., DeepHealth, Radformation Inc., MVision AI Ltd., Mirada Medical Ltd., ViewRay Inc., Oncora Medical, Enlitic, Optellum Ltd.
View The Full Artificial Intelligence (AI) Tele-Oncology Radiation Dose Scheduler Market Report:
Artificial Intelligence (AI) Tele-Oncology Radiation Dose Scheduler Market Largest Region: Which Geography Holds The Biggest Share?
North America was the largest region in the AI tele-oncology radiation dose scheduler market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI) tele-oncology radiation dose scheduler market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
